All patients
critical disease severe disease
sarilumab in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
REMAP-CAP sarilumab, 2021 0.51 [0.25; 1.07]
sarilumab phase 2 high dose, 0 0.78 [0.34; 1.80]
sarimulab phase 2 low dose, 0 1.51 [0.69; 3.32]
0.91 [0.61 ; 1.35 ] Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, REMAP-CAP sarilumab, 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0 5 11% 1,212 serious not evaluable clinical improvementdetailed results Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
REMAP-CAP sarilumab, 2021 1.76 [1.12; 2.78]
sarilumab phase 2 high dose, 0 2.09 [1.00; 4.36]
sarimulab phase 2 low dose, 0 1.51 [0.73; 3.11]
1.43 [1.01 ; 2.04 ] Lescure (Sarilumab 200mg), 2021, REMAP-CAP sarilumab, 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0 4 46% 967 serious not evaluable clinical improvement (14-day)detailed results REMAP-CAP sarilumab, 2021 1.86 [1.20; 2.87]
1.86 [1.20 ; 2.87 ] REMAP-CAP sarilumab, 2021 1 0% 450 NA not evaluable clinical improvement (time to event analysis only)detailed results Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
1.09 [0.87 ; 1.35 ] Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021 2 0% 506 moderate not evaluable death or ventilationdetailed results sarilumab phase 2 high dose, 0 0.39 [0.18; 0.82]
sarimulab phase 2 low dose, 0 0.70 [0.34; 1.44]
0.53 [0.30 ; 0.94 ] sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0 2 20% 270 serious not evaluable mechanical ventilationdetailed results sarilumab phase 2 high dose, 0 0.27 [0.10; 0.71]
sarimulab phase 2 low dose, 0 0.28 [0.11; 0.73]
0.27 [0.14 ; 0.55 ] sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0 2 0% 270 serious not evaluable off oxygenationdetailed results sarilumab phase 2 high dose, 0 1.99 [0.95; 4.15]
sarimulab phase 2 low dose, 0 1.07 [0.52; 2.21]
1.46 [0.79 ; 2.68 ] sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0 2 28% 270 serious not evaluable serious adverse eventsdetailed results Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
1.26 [0.82 ; 1.94 ] Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021 2 0% 502 moderate not evaluable adverse eventsdetailed results Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
1.13 [0.77 ; 1.67 ] Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021 2 0% 502 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-26 07:58 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 91
- treatments: 553,628,646,645
- roots T: 290
